Multiple grass mixes as opposed to single grasses for allergen immunotherapy in allergic rhinitis

Clinical and Experimental Allergy

Volumn 43, Issue 11, 2013, Pages 1202-1216

  Gangl, K ^a   Niederberger, V ^a   Valenta, R ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

GRASS POLLEN EXTRACT; GRASS POLLEN VACCINE; RECOMBINANT ALLERGEN; RECOMBINANT TIMOTHY GRASS POLLEN ALLERGEN; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; CROSS REACTION; DRUG EFFICACY; GRASS; GRASS POLLEN; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; NONHUMAN; PHLEUM PRATENSE; POLLEN ALLERGY; PRIORITY JOURNAL; REVIEW; SPECIES DIFFERENCE; SUBCUTANEOUS IMMUNOTHERAPY;

ALLERGENS; CROSS REACTIONS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; PLANT EXTRACTS; POACEAE; POLLEN; RHINITIS, ALLERGIC, PERENNIAL;

EID: 84886285872     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12128     Document Type: Review

References (126)

1. Wüthrich B, Schindler C, Leuenberger P, Ackermann-Liebrich U. Prevalence of atopy and pollinosis in the adult population of Switzerland (SAPALDIA study). Swiss study on air pollution and lung diseases in adults. Int Arch Allergy Immunol 1995; 106:149-56.
2. Burbach GJ, Heinzerling LM, Edenharter G et al. GA(2)LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe. Allergy 2009; 64:1507-15.
3. Suphioglu C. What are the important allergens in grass pollen that are linked to human allergic disease? Clin Exp Allergy 2000; 30:1335-41.
4. Suphioglu C, Singh MB, Taylor P et al. Mechanism of grass-pollen-induced asthma. Lancet 1992; 339:569-72.
5. Larché M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006; 6:761-71.
6. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102:558-62.
7. Noon L. Prophylactic inoculation against hay fever. Lancet 1911; I:1572-3.
8. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheik A, Druham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007; 1:CD001936. doi:10.1002/14651858.CD001936.pub2.
9. Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468-75.
10. Möller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109:251-6.
11. Focke M, Marth K, Flicker S, Valenta R. Heterogeneity of commercial timothy grass pollen extracts. Clin Exp Allergy 2008; 38:1400-8.
12. Valenta R, Ferreira F, Focke-Tejkl M et al. From allergen genes to allergy vaccines. Annu Rev Immunol 2010; 28:211-41.
13. Hiller R, Laffer S, Harwanegg C et al. Microarrayed allergen molecules: diagnostic gatekeepers for allergy therapy. FASEB 2002; 16:414-6.
14. Frew AJ. Allergen immunotherapy. J Allergy Clin Immunol 2010; 125:S306-13.
15. Nelson HS. Allergen immunotherapy: where is it now? J Allergy Clin Immunol 2007; 119:767-77.
16. Weber R. Patterns of pollen cross-allergenicity. J Allergy Clin Immunol 2003; 112:229-39.
17. Johansen N, Weber RW, Ipsen H, Barber D, Broge L, Hejl C. Extensive IgE cross-reactivity towards the Pooideae grasses substantiated for a large number of grass-pollen-sensitized subjects. Int Arch Allergy Immunol 2009; 150:325-34.
18. Hejl C, Wurtzen PA, Kleine-Tebbe J, Johansen N, Broge L, Ipsen H. Phleum pratense alone is sufficient for allergen specific immunotherapy against allergy to Pooideae grass pollens. Clin Exp Allergy 2009; 39:752-9.
19. Chabre H, Gouyon B, Huet A et al. Molecular variability of group 1 and 5 grass pollen allergens between Pooideae species: implications for immunotherapy. Clin Exp Allergy 2010; 40:505-19.
20. Grubb GD, Vaughan WT. Evidence of group specific and species specific sensitization to pollen. J Allergy 1938; 9:211-26.
21. Marcucci F, Sensi L, Di Cara G et al. Which allergen extract for grass pollen immunotherapy? An in vitro study. Immunol Invest 2010; 39:635-44.
22. Martínez-Cócera C, Sastre J, Cimarra M et al. Immunotherapy with a Phleum pratense allergen extract induces an immune response to a grass-mix allergen extract. J Investig Allergol Clin Immunol 2010; 20:13-9.
23. Andersson K, Lidholm J. Characteristics and immunobiology of grass pollen allergens. Int Arch Allergy Immunol 2003; 130:87-107.
24. Simon BK, Clayton WD, Harman KT et al. Grass World 2011. http://grassworld.myspecies.info/ (Accessed on 12 November 2012).
25. Knox RB. Grass pollen, thunderstorms and asthma. Clin Exp Allergy 1993; 23:354-9.
26. Vrtala S, Grote M, Duchene M et al. Properties of tree and grass pollen allergens: reinvestigation of the linkage between solubility and allergenicity. Int Arch Allergy Immunol 1993; 102:160-9.
27. Grote M, Vrtala S, Niederberger V, Wiermann R, Valenta R, Reichelt R. Release of allergen- bearing cytoplasm from hydrated pollen: a mechanism common to a variety of grass (Poaceae) species revealed by electron microscopy. J Allergy Clin Immunol 2001; 108:109-15.
28. Løwenstein H. Immunological partial identity and in vitro inhibitory effect of two major timothy pollen allergens to whole pollen extract of four grasses. Int Arch Allergy Appl Immunol 1978; 57:379-83.
29. Chakrabarty S, Løwenstein H, Ekramoddoullah AK, Kisil FT, Sehon AH. Detection of cross-reactive allergens in Kentucky bluegrass pollen and six other grasses by crossed radioimmunoelectrophoresis. Int Arch Allergy Appl Immunol 1981; 66:142-57.
30. Kazemi-Shirazi L, Niederberger V, Linhart B, Lidholm J, Kraft D, Valenta R. Recombinant marker allergens: diagnostic gatekeepers for the treatment of allergy. Int Arch Allergy Immunol 2002; 127:259-68.
31. Ferreira F, Hawranek T, Gruber P, Wopfner N, Mari A. Allergic cross-reactivity: from gene to clinic. Allergy 2004; 59:243-67.
32. Valenta R, Duchene M, Ebner C et al. profilins constitute a novel family of functional plant pan-allergens. J Exp Med 1992; 175:377-85.
33. Johnson P, Marsh DG. 'Isoallergens' from rye grass pollen. Nature 1965; 206:935-7.
34. Perez M, Ishioka GY, Walker LE, Chesnut RW. cDNA cloning immunological characterization of the rye grass allergen Lol p I. J Biol Chem 1990; 265:16210-5.
35. Griffith IJ, Smith PM, Pollock J et al. Cloning and sequencing of Lol pI, the major allergenic protein of rye-grass pollen. FEBS Lett 1991; 279:210-5.
36. Laffer S, Valenta R, Vrtala S et al. Complementary DNA cloning of the major allergen Phl p I from timothy grass (Phleum pratense); recombinant Phl p I inhibits IgE binding to group I allergens from eight different grass species. J Allergy Clin Immunol 1994; 94:689-98.
37. Van Ree R, van Leeuwen WA, Aalberse RC. How far can we simplify in vitro diagnostics for grass pollen allergy? A study with 17 whole pollen extracts and purified natural and recombinant allergens. J Allergy Clin Immunol 1998; 102:184-90.
38. Laffer S, Duchene M, Reimitzer I et al. Common IgE-epitopes of recombinant Phl p I, the major timothy grass pollen allergen and natural group I grass pollen isoallergens. Mol Immunol 1996; 33:417-26.
39. Laffer S, Vrtala S, Duchêne M et al. IgE-binding capacity of recombinant timothy grass (Phleum pratense) pollen allergens. J Allergy Clin Immunol 1994; 94:88-94.
40. Suck R, Hagen S, Cromwell O, Fiebig H. Rapid and efficient purification of Phleum pratense major allergens Phl p 1 and group Phl p 2/3 using a two-step procedure. J Immunol Methods 1999; 229:73-80.
41. Suck R, Hagen S, Cromwell O, Fiebig H. The high molecular mass allergen fraction of timothy grass pollen (Phleum pratense) between 50-60 kDa is comprised of two major allergens: Phl p 4 and Phl p 13. Clin Exp Allergy 2000; 30:1395-1402.
42. Petersen A, Suck R, Hagen S, Cromwell O, Fiebig H, Becker W-M. Group 13 grass allergens: structural variability between different grass species and analysis of proteolytic stability. J Allergy Clin Immunol 2001; 107:856-62.
43. Grote M, Swoboda I, Valenta R, Reichelt R. Group 13 allergens as environmental and immunological markers for grass pollen allergy: studies by immunogold field emission scanning and transmission electron microscopy. Int Arch Allergy Immunol 2005; 136:303-10.
44. Swoboda I, Grote M, Verdino P et al. Molecular characterization of polygalacturonases as grass pollen-specific marker allergens: expulsion from pollen via submicronic respirable particles. J Immunol 2004; 15:172.
45. Westritschnig K, Horak F, Swoboda I et al. Different allergenic activity of grass pollen allergens revealed by skin testing. Eur J Clin Invest 2008; 38:260-7.
46. Vrtala S, Sperr WR, Reimitzer I et al. cDNA cloning of a major allergen from timothy grass (Phleum pratense) pollen; characterization of the recombinant Phl pV allergen. J Immunol 1993; 151:4773-81.
47. Flicker S, Vrtala S, Steinberger P et al. A human monoclonal IgE antibody defines a highly allergenic fragment of the major timothy grass pollen allergen, Phl p 5: molecular, immunological, and structural characterization of the epitope-containing domain. J Immunol 2000; 165:3849-59.
48. Niederberger V, Stubner P, Spitzauer S et al. Skin test results but not serology reflect immediate type respiratory sensitivity: a study performed with recombinant allergen molecules. J Invest Dermatol 2001; 117:848-51.
49. Niederberger V, Laffer S, Fröschl R et al. IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5 andBet v 2) account for a high percentage of grass pollen-specific IgE. J Allergy Clin Immunol 1998; 101:258-64.
50. Westritschnig K, Sibanda E, Thomas W et al. Analysis of the sensitization profile towards allergens in central Africa. Clin Exp Allergy 2003; 33:22-7.
51. Dolecek C, Vrtala S, Laffer S et al. Molecular characterization of Phl p II, a major timothy grass (Phleum pratense) pollen allergen. FEBS Lett 1993; 335:299-304.
52. Petersen A, Suck R, Lindner B et al. Phl p 3: structural and immunological characterization of a major allergen of timothy grass pollen. Clin Exp Allergy 2006; 36:840-9.
53. Vrtala S, Fischer S, Grote M et al. Molecular, immunological, and structural characterization of Phl p 6, a major allergen and P-particle-associated protein from Timothy grass (Phleum pratense) pollen. J Immunol 1999; 163:5489-96.
54. Marknell DeWitt A, Niederberger V, Lehtonen P et al. Molecular and immunological characterization of a novel timothy grass (Phleum pratense) pollen allergen, Phl p 11. Clin Exp Allergy 2002; 32:1329-40.
55. van Ree R, Hoffman DR, van Dijk W et al. Lol p XI, a new major grass pollen allergen, is a member of a family of soybean trypsin inhibitor-related proteins. J Allergy Clin Immunol 1995; 95:970-8.
56. Niederberger V, Hayek B, Vrtala S et al. Calcium-dependent immunoglobulin E recognition of the apo- and calcium-bound form of a cross-reactive two EF-hand timothy grass pollen allergen, Phl p 7. FASEB J 1999; 13:843-56.
57. Valenta R, Duchêne M, Pettenburger K et al. Identification of profilin as a novel pollen allergen; IgE autoreactivity in sensitized individuals. Science 1991; 253:557-60.
58. Stumvoll S, Lidholm J, Thunberg R et al. Purification, structural and immunological characterization of a timothy grass (Phleum pratense) pollen allergen, Phl p 4, with cross-reactive potential. Biol Chem 2002; 383:1383-96.
59. DeWitt AM, Andersson K, Peltre G, Lidholm J. Cloning, expression and immunological characterization of full-length timothy grass pollen allergen Phl p 4, a berberine bridge enzyme-like protein with homology to celery allergen Api g 5. Clin Exp Allergy 2006; 36:77-86.
60. Henzgen M, Wenz W, Strümpfel R. Experiences with desensitization of early spring pollen allergy using 2 tree pollen extracts. Z Gesamte Inn Med 1989; 44:691-3.
61. Petersen BN, Janniche H, Munch EP et al. Immunotherapy with partially purified and standardized tree pollen extracts. I. Clinical results from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel. Allergy 1988; 43:353-62.
62. Wihl JA, Ipsen H, Petersen BN, Munch EP, Janniche H, Løwenstein H. Immunotherapy with partially purified and standardized tree pollen extracts. II. Results of skin prick tests and nasal provocation tests from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel. Allergy 1988; 44(Suppl):1-42.
63. Ipsen H, Schwartz B, Wihl JA et al. Immunotherapy with partially purified and standardized tree pollen extracts. III. Specific IgE response to the major allergens of alder, birch and hazel pollen during immunotherapy. Allergy 1988; 43:370-7.
64. Frostad AB, Grimmer O, Sandvik L, Moxnes A, Aas K. Clinical effects of hyposensitization using a purified allergen preparation from Timothy pollen as compared to crude aqueous extracts from Timothy pollen and a four-grass pollen mixture respectively. Clin Allergy 1983; 13:337-57.
65. Verstraeten JM, Verstraeten AF. Clinical evaluation of hyposensitization in allergic rhinitis: comparison of the results obtained with three different extracts. Material from a 3-year study. Ann Allergy 1987; 58:416-20.
66. Aalberse RC, Koshte V, Clemens JG. Immunoglobulin E antibodies that crossreact with vegetable foods, pollen, and Hymenoptera venom. J Allergy Clin Immunol 1981; 68:356-64.
67. Mari A. IgE to cross-reactive carbohydrate determinants: analysis of the distribution and appraisal of the in vivo and in vitro reactivity. Int Arch Allergy Immunol 2002; 129:286-95.
68. Manduzio H, Fitchette AC, Hrabina M et al. Glycoproteins are species-specific markers and major IgE reactants in grass pollens. Plant Biotechnol J 2012; 10:184-94.
69. van der Veen MJ, van Ree R, Aalberse RC et al. Poor biologic activity of cross-reactive IgE directed to carbohydrate determinants of glycoproteins. J Allergy Clin Immunol 1997; 100:327-34.
70. Altmann F. The role of protein glycosylation in allergy. Int Arch Allergy Immunol 2007; 142:99-115.
71. Valenta R. Biochemistry of allergens and recombinant allergens. In: Kay AB, Kaplan AP, Bousquet J, Holt PG, eds. Allergy and allergic diseases, 2nd edition. London: Wiley-Blackwell, 2008:895-911.
72. Mari A, Scala E. Allergenic extracts for specific immunotherapy: to mix or not to mix? Int Arch Allergy Immunol 2006; 141:57-60.
73. Løwenstein H, Wihl JA, Bache Billesbølle K, Bøwadt H. Rationale for specific immunotherapy of grass pollen allergy with extracts of rye pollen. Skin test reactivity and immunochemical relationship between pollen allergens from rye and other common grasses. Allergy 1984; 39:421-32.
74. Valenta R, Vrtala S, Ebner C, Kraft D, Scheiner O. Diagnosis of grass pollen allergy with recombinant timothy grass (Phleum pratense) pollen allergens. Int Arch Allergy Immunol 1992; 97:287-94.
75. Laffer S, Spitzauer S, Susani M et al. Comparison of recombinant timothy grass pollen allergens with natural extract for diagnosis of grass pollen allergy in different populations. J Allergy Clin Immunol 1996; 98:652-8.
76. Aalberse RC. Structural biology of allergens. J Allergy Clin Immunol 2000; 106:228-38.
77. Ferreira F, Hirtenlehner K, Jilek A et al. Dissection of Immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy. J Exp Med 1996; 183:599-609.
78. Gehlhar K, Petersen A, Schramm G, Becker WM, Schlaak M, Bufe A. Investigation of different recombinant isoforms of grass group-V allergens (timothy grass pollen) isolated by low-stringency cDNA hybridization - antibody binding capacity and allergenic activity. Eur J Biochem 1997; 247:217-23.
79. Fedorov AA, Ball T, Mahoney NM, Valenta R, Almo SC. The molecular basis for allergen cross-reactivity: crystal structure and IgE-epitope mapping of birch pollen profilin. Structure 1997; 5:33-45.
80. Flicker S, Steinberger P, Ball T et al. Spatial clustering of the IgE epitopes on the major timothy grass pollen allergen Phl p 1: importance for allergenic activity. J Allergy Clin Immunol 2006; 117:1336-43.
81. Duffort O, Quintana J, Ipsen H, Barber D, Polo F. Antigenic similarity among group 1 allergens from grasses and quantitation ELISA using monoclonal antibodies to Phl p 1. Int Arch Allergy Immunol 2008; 145:283-90.
82. Davies JM, Dang TD, Voskamp A et al. Functional immunoglobulin E cross-reactivity between Pas n 1 of Bahia grass pollen and other group 1 grass pollen allergens. Clin Exp Allergy 2011; 41:281-91.
83. Davies JM, Li H, Green M, Towers M, Upham JW. Subtropical grass pollen allergens are important for allergic respiratory diseases in subtropical regions. Clin Transl Allergy 2012; 2:4.
84. Focke-Tejkl M, Valenta R. Safety of engineered allergen-specific immunotherapy vaccines. Curr Opin Allergy Clin Immunol 2012; 12:555-63.
85. Valenta R, Campana R, Marth K, van Hage M. Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches. J Intern Med 2012; 272:144-57.
86. Linhart B, Valenta R. Vaccines for allergy. Curr Opin Immunol 2012; 24:354-60.
87. Cromwell O, Niederberger V, Horak F, Fiebig H. Clinical experience with recombinant molecules for allergy vaccination. Curr Top Microbiol Immunol 2011; 352:27-42.
88. Rancitelli P, Hofmann A, Burks AW. Vaccine approaches for food allergy. Curr Top Microbiol Immunol 2011; 352:55-69.
89. Valenta R, Niespodziana K, Focke-Tejkl M et al. Recombinant allergens: what does the future hold? J Allergy Clin Immunol 2011; 127:860-4.
90. Pauli G, Malling HJ. Allergen-specific immunotherapy with recombinant allergens. Curr Top Microbiol Immunol 2011; 352:43-54.
91. Cromwell O, Häfner D, Nandy A. Recombinant allergens for specific immunotherapy. J Allergy Clin Immunol 2011; 127:865-72.
92. Valenta R, Linhart B, Swoboda I, Niederberger V. Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immuno-therapy with recombinant allergens. Allergy 2011; 66:775-83.
93. Gilles S, Mariani V, Bryce M et al. Pollen allergens do not come alone: pollen associated lipid mediators (PALMS) shift the human immune systems towards a T(H)2-dominated response. Allergy Asthma Clin Immunol 2009; 5:3.
94. Chapman MD, Ferreira F, Villalba M et al. CREATE consortium, The European Union CREATE project: a model for international standardization of allergy diagnostics and vaccines. J Allergy Clin Immunol 2008; 122:882-9.
95. Moingeon P, Hrabina M, Bergmann KC et al. Specific immunotherapy for common grass pollen allergies: pertinence of a five grass pollen vaccine. Int Arch Allergy Immunol 2008; 146:338-342.
96. Seppälä U, Dauly C, Robinson S, Hornshaw M, Larsen JN, Ipsen H. Absolute quantification of allergens from complex mixtures: a new sensitive tool for standardization of allergen extracts for specific immunotherapy. J Proteome Res 2011; 10:2113-22.
97. Arilla MC, Ibarrola I, Eraso E, Aguirre M, Martínez A, Asturias JA. Quantification in mass units of group 1 grass allergens by a monoclonal antibody-based sandwich ELISA. Clin Exp Allergy 2001; 31:1271-8.
98. Gavrović MD, Trtić T, Vujcić Z, Petrović S, Jankov RM. Comparison of allergenic potentials of timothy (Phleum pratense) pollens from different pollen seasons collected in the Belgrade area. Allergy 1997; 52:210-4.
99. Esch R. Evaluation of allergen vaccine potency. Curr Allergy Asthma Rep 2006; 6:402-6.
100. Eckl-Dorna J, Klein B, Reichenauer TG, Niederberger V, Valenta R. Exposure of rye (Secale cereale) cultivars to elevated ozone levels increases the allergen content in pollen. J Allergy Clin Immunol 2010; 126:1315-7.
101. Calderón M, Cardona V, Demoly P; EAACI 100 Years of Immunotherapy Experts Panel, One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswered questions. Allergy 2012; 67:462-76.
102. Van der Veen MJ, Mulder M, Witteman AM et al. False-positive skin prick test responses to commercially available dog dander extract caused by contamination with house dust mite (Dermatophagoides pteronyssinus) allergens. J Allergy Clin Immunol 1996; 98:1028-34.
103. Trivedi B, Valerio C, Slater JE. Endotoxin content of standardized allergen vaccines. J Allergy Clin Immunol 2003; 111:777-83.
104. Baeyens-Volant D, M'Rabet N, El Mahyaoui R, Wattiez R, Azarkan M. Contaminant trypsin-like activity from the timothy grass pollen is responsible for the conflicting enzymatic behavior of the major allergen Phl p 1, Biochim. Biophys. Acta 2013; 1834:272-83.
105. Valenta R, Niederberger V. Recombinant allergens for immunotherapy. J Allergy Clin Immunol 2007; 119:826-30.
106. Focke M, Swoboda I, Marth K, Valenta R. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy 2010; 40:385-97.
107. Linhart B, Valenta R. Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives. Vaccine 2012; 30:4328-35.
108. Swoboda I, De Weerd N, Bhalla PL et al. Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapy. Eur J Immunol 2002; 32:270-80.
109. Westritschnig K, Focke M, Verdino P et al. Generation of an allergy vaccine by disruption of the three-dimensional structure of the cross-reactive calcium-binding allergen, Phl p 7. J Immunol 2004; 172:5684-92.
110. Vrtala S, Focke M, Kopec J et al. Genetic engineering of the major timothy grass pollen allergen, Phl p 6, to reduce allergenic activity and preserve immunogenicity. J Immunol 2007; 179:1730-9.
111. Westritschnig K, Linhart B, Focke-Tejkl M et al. A hypoallergenic vaccine obtained by tail-to-head restructuring of timothy grass pollen profilin, Phl p 12, for the treatment of cross-sensitization to profilin. J Immunol. 2007; 179:7624-34.
112. Ball T, Linhart B, Sonneck K et al. Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination. Allergy 2009; 64:569-80.
113. Mothes-Luksch N, Stumvoll S, Linhart B et al. Disruption of allergenic activity of the major grass pollen allergen Phl p 2 by reassembly as a mosaic protein. J Immunol 2008; 181:4864-73.
114. Linhart B, Mothes-Luksch N, Vrtala S, Kneidinger M, Valent P, Valenta R. A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6. Biol Chem 2008; 389:925-33.
115. Wald M, Kahlert H, Reese G et al. Hypoallergenic mutants of the Timothy grass pollen allergen Phl p 5 generated by proline mutations. Int Arch Allergy Immunol 2012; 159:130-42.
116. Linhart B, Jahn-Schmid B, Verdino P et al. Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. FASEB J 2002; 16:1301-3.
117. Linhart B, Hartl A, Jahn-Schmid B et al. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J Allergy Clin Immunol 2005; 115:1010-6.
118. Metz-Favre C, Linhart B, Focke-Tejkl M et al. Skin test diagnosis of grass pollen allergy with a recombinant hybrid molecule. J Allergy Clin Immunol 2007; 120:315-21.
119. Edlmayr J, Niespodziana K, Linhart B et al. A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1. J Immunol. 2009; 182:6298-306.
120. Edelmayr J, Niespodziana K, Focke-Tejkl M, Linhart B, Valenta R. Allergen-specific immunotherapy: towards combination vaccines for allergic and infectious diseases. In: Valenta R, Coffman RL, eds. Vaccines against allergies, current topics in microbiology and immunology, Vol. 352, Berlin-Heidelberg: Springer Verlag, 2011: 121-40.
121. Lorenz AR, Luttkopf D, Seitz R, Vieths S. The regulatory system in europe with special emphasis on allergen products. Int Arch Allergy Immunol 2008; 147:263-75.
122. Niederberger V, Horak F, Vrtala S et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci 2004; 101(Suppl 2):14677-82.
123. Pauli G, Larsen TH, Rak S et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjuncti- vitis. J Allergy Clin Immunol 2008; 122:951-60.
124. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005; 116:608-13.
125. Klimek L, Schendzielorz P, Pinol R, Pfaar O. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study. Clin Exp Allergy 2012; 42:936-45.
126. Sastre J, Landivar ME, Ruiz-García M, Andregnette-Rosigno MV, Mahillo I. How molecular diagnosis can change allergen-specific immunotherapy prescription in a complex pollen area. Allergy 2012; 67:709-11.